Levofloxacin antibiotic with IV clot-busting for acute stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether adding the antibiotic levofloxacin to standard IV clot-busting treatment is safe and improves outcomes after an acute ischemic stroke. It may help by reducing complications related to infection or inflammation, but you must meet specific heart, liver, kidney, and medication-safety rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old
- You had an acute ischemic stroke treated with IV alteplase (0.9 mg/kg)
- Before the stroke, you were fully independent or nearly so (mRS 0–1), and now your stroke severity is moderate (NIHSS 5–15)
- You did not have a blood vessel procedure to remove the clot (endovascular treatment)
- You have no allergy to levofloxacin or other similar antibiotics, and you have not taken quinolone antibiotics or certain heart rhythm medicines within 14 days
- Your heart rhythm, liver, kidneys, and overall health tests are within safe limits, and there is no active infection or confirmed bleeding in the brain
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the antibiotic levofloxacin can be given soon after an acute ischemic stroke to improve outcomes and monitor side effects. It’s for people with a moderate stroke severity who are not having certain emergency treatments or infections.
This trial tests whether giving tirofiban (a blood thinner) shortly after the standard clot-busting drug tenecteplase can improve recovery from a moderate stroke. It is for people who have had a stroke within the last few hours and do not have certain risk factors like irregular heart rhythm or recent bleeding.
This trial tests whether a clot-busting medication given through a vein (intravenous thrombolysis) can safely treat acute ischemic stroke within 24 hours in people who have taken a newer oral blood thinner (NOAC) within the last 4 to 48 hours.
This trial tests a medication called tirofiban given intravenously after standard thrombolysis to see if it improves recovery in people with acute ischemic stroke. It is for those whose symptoms have not improved or are getting worse after initial treatment.
This trial tests whether adding a second medicine (tirofiban) to standard clot-busting treatment can help people who are not improving after the first hour. It is for people with a moderate to severe stroke who are not candidates for a clot-removal procedure.
This trial tests whether a clot-busting drug given through a vein can safely and effectively treat strokes in people who also have active cancer. It aims to see if this treatment can improve recovery without increasing bleeding risks.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.